TY - JOUR
T1 - Addressing the issue of bias in observational studies
T2 - Using instrumental variables and a quasi-randomization trial in an ESME research project
AU - ESME Group
AU - Ezzalfani, Monia
AU - Porcher, Raphaël
AU - Savignoni, Alexia
AU - Delaloge, Suzette
AU - Filleron, Thomas
AU - Robain, Mathieu
AU - Pérol, David
AU - Arveux, Patrick
AU - Bachelot, Thomas
AU - Delaine, Stephanie
AU - Berchery, Delphine
AU - Brain, Etienne
AU - Breton, Mathias
AU - Campion, Loic
AU - Chamorey, Emmanuel
AU - Dejean, Valerie
AU - Guizard, Anne Valerie
AU - Jaffre, Anne
AU - Laborde, Lilian
AU - Laurent, Carine
AU - Lebitasy, Marie Paule
AU - Loeb, Agnes
AU - Mons, Muriel
AU - Parent, Damien
AU - Perrocheau, Genevieve
AU - Mouret-Reynier, Marie Ange
AU - Velten, Michel
N1 - Publisher Copyright:
© 2021 Ezzalfani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Purpose Observational studies using routinely collected data are faced with a number of potential shortcomings that can bias their results. Many methods rely on controlling for measured and unmeasured confounders. In this work, we investigate the use of instrumental variables (IV) and quasi-trial analysis to control for unmeasured confounders in the context of a study based on the retrospective Epidemiological Strategy and Medical Economics (ESME) database, which compared overall survival (OS) with paclitaxel plus bevacizumab or paclitaxel alone as first-line treatment in patients with HER2-negative metastatic breast cancer (MBC). Patients and methods Causal interpretations and estimates can be made from observation data using IV and quasi-trial analysis. Quasi-trial analysis has the same conceptual basis as IV, however, instead of using IV in the analysis, a “superficial” or “pseudo” randomized trial is used in a Cox model. For instance, in a multicenter trial, instead of using the treatment variable, quasi-trial analysis can consider the treatment preference in each center, which can be informative, and then comparisons of results between centers or clinicians can be informative. Results In the original analysis, the OS adjusted for major factors was significantly longer with paclitaxel and bevacizumab than with paclitaxel alone. Using the center-treatment preference as an instrument yielded to concordant results. For the quasi-trial analysis, a Cox model was used, adjusted on all factors initially used. The results consolidate those obtained with a conventional multivariate Cox model. Conclusion Unmeasured confounding is a major concern in observational studies, and IV or quasi-trial analysis can be helpful to complement analysis of studies of this nature.
AB - Purpose Observational studies using routinely collected data are faced with a number of potential shortcomings that can bias their results. Many methods rely on controlling for measured and unmeasured confounders. In this work, we investigate the use of instrumental variables (IV) and quasi-trial analysis to control for unmeasured confounders in the context of a study based on the retrospective Epidemiological Strategy and Medical Economics (ESME) database, which compared overall survival (OS) with paclitaxel plus bevacizumab or paclitaxel alone as first-line treatment in patients with HER2-negative metastatic breast cancer (MBC). Patients and methods Causal interpretations and estimates can be made from observation data using IV and quasi-trial analysis. Quasi-trial analysis has the same conceptual basis as IV, however, instead of using IV in the analysis, a “superficial” or “pseudo” randomized trial is used in a Cox model. For instance, in a multicenter trial, instead of using the treatment variable, quasi-trial analysis can consider the treatment preference in each center, which can be informative, and then comparisons of results between centers or clinicians can be informative. Results In the original analysis, the OS adjusted for major factors was significantly longer with paclitaxel and bevacizumab than with paclitaxel alone. Using the center-treatment preference as an instrument yielded to concordant results. For the quasi-trial analysis, a Cox model was used, adjusted on all factors initially used. The results consolidate those obtained with a conventional multivariate Cox model. Conclusion Unmeasured confounding is a major concern in observational studies, and IV or quasi-trial analysis can be helpful to complement analysis of studies of this nature.
UR - http://www.scopus.com/inward/record.url?scp=85115327158&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0255017
DO - 10.1371/journal.pone.0255017
M3 - Article
C2 - 34525119
AN - SCOPUS:85115327158
SN - 1932-6203
VL - 16
JO - PLoS ONE
JF - PLoS ONE
IS - 9 September
M1 - e0255017
ER -